Perhaps the most impactful and foreboding development in chronic diseas es in recent decades has been the increasing prevalence and awareness of dementia. The various dementias, especially Alzheimer disease (AD) , have de railed and ended the lives of tens of millions in America and worldwide. It is a truism that AD patients die twice. First the mind dies, and only later does the body. AD uniquely and unremittingly affects not only patients, but their families, caregivers, and communities. In recent years, AD may have displaced cancer as the most feared disease among Americans. As with other diseases that have no meaningful methods for prevention and treatment, research tar geting AD has primarily focused on preclinical approaches, predominantly us ing animals. Nonetheless, decades of animal research have failed to translate into significant advances in the prevention or treatment of AD. In view of this failure, a different and human-relevant approach is critically needed.
Animal Basic Science Research and Correlations
Most basic science research of AD has used animals, predominantly mice (transgenic, inbred, and wild-type) (Cavanaugh, Pippin and Barnard, 2014; Do Carmo and Cuello, 2013; Jackson Laboratory, 2017; Webster et al., 2014 (Alz forum, 2017; Charles River, 2017; Jackson Laboratory, 2017; Taconic Biosciences, 2017 ) . Extensive lists of animal models for AD basic science research and drug development have been published, including information on specific genetic configurations and how these animals have been used ( Cavanaugh, Pippin and Barnard, 2014; Kumar et al., 2016; Neha et al., 2014; Puzzo et al., 2014) .
Because postmortem studies have identified specific brain pathologies among AD patients, most notably extracellular beta-amyloid (AB) plaques and intracellular neurofibrillary tangles (NFT), the great majority of basic sci ence research has used genetically modified animals to produce similar brain pathologies. AB plaques have been associated with localized inflammation, contributing to the neuronal and synaptic network damage believed to be related to AD symptoms and disease progression (Eikelenboom et al., 1989; Eikelenboom and Veerhuis, 1996; Rosenberg, 200s; Veerhuis, 2011) . The ability to produce AB plaques and NFT in animal models has been available for more than three decades (Glenner and Wong, 1984; Kosik, Joachim and Selkoe, 1986; Wood et al., 1986) . AB plaques are also formed, then often broken down and re moved in healthy human brains; but they persist and accumulate in AD brains. Further complicating the relationship between AB plaques and AD, studies have shown that 14°/0-21% of clinically diagnosed patients have zero or mini mal brain AB plaques on postmortem examination (Beach et al., 2012; Beekly et al., 2007; Serrano-Pozo et al., 2014 (Kosik, Joachim and Selkoe, 1986; Wood et al., 1986) ( Cavanaugh, Pippin and Barnard, 2014; Masters et al., 1985; Ross and Poirier, 2004) .
Mutations in genes encoding amyloid precursor protein (APP), as well as the gamma secretase catalytic proteins presenilin 1 (PSEN1) and presenilin 2 (PSEN2), have also been linked to familial AD and have been employed in the study of the disease in animals (Borchelt, et al., 1997; Chartier-Harlin et al., 1991; Goate et al., 1991; Levy-Lehad et al., 199s; Mullan et al., 1992 ( Corder et al., 1993; Rossor et al., 1996; Sadigh-Eteghad et al., 2012; Strittmatter et al., 1993 ( Oddo et al., 2003) .
The senescence-accelerated mouse prone 8 (sAMP8) strain with a mean lifespan of 9.7 months is considered by researchers to be more suitable to investigate late-onset AD (Pallas, 2012) . SAMP8 mice exhibit dendritic spine loss, spongiosis, gliosis, and forebrain cholinergic deficits, while develop ing A� deposits and aberrant h yp erphosphorylated tau-like NFTs ( Cheng, Zhou and Zhang, 2014 (Lok et al., 2013; Porquet et al., 2015) (Porquet et al., 2015) . Further information, regarding the specific animal models, their phenotyp ic results, and their contributions to the knowledge base for animal surrogates of human AD and some important biological and outcome differences, is avail able ( e.g., Cavanaugh, Pippin and Barnard, 2014; Esquerda-Canals et al., 2017; Geerts, 2009; Kumar et al., 2016 (Dodart et al., 2002; Duyckaerts, Potier and Delatour, 2008 (Neha et al., 2014) Cavanaugh, Pippin and Barnard, 2014; Langley, 2014 Berk and Sabbagh, 2013; Cava naugh, Pippin and Barnard, 2014; Langley, 2014; Schneider et al., 2014 (FDA, 2004; Mitka, 2006; Singh and Hen ske, 2003 ( Arrowsmith, 20na; Arrowsmith, 2onb; Lovell-Badge, 2013 (Delrieu et al., 2011) (Cummings, Morstorf and Lee, 2016 (Henriques, 2017; Us Against Alzheimer's, 2017) . to improvement other than the replacement of the failed animal research par adigm by a commitment to human-relevant research methods.
Whither the Amyloid Cascade Hypothesis?
The amyloid cascade h yp othesis, in its initial description (Hardy and Allsop, 1991; Hardy and Higgins, 1992) (Baker-Nigh et al., 2015) and older persons (Armstrong et al., 1996; Esparza et al., 2013; Haroutunian et al., 2008; Mansell et al., 2013; Price et al., 2009 ) (Jansen, et al., 2015) . Lon Schneider of the University of Southern California, Keck School of Medicine, stated that: "There are people who die with a head full of amyloid and have no cogni tive impairment whatsoever" (Mullin, 2017 ) . Conversely, AB plaques may be absent or minimally present in clinically diagnosed AD patients (Mansell et al., 2015; Morris, Clark and Vissel, 2014; Terry et al., 1991) . A recent report demonstrates that tau oligomers, produced subsequent to AE deposition, are also present in the sera of aged normal controls as well as AD patients (Ko larova et al., 2017) . It has been reported that some degree of tau pathology is ubiquitous in postmortem human brains (Braak and Braak, 1997; Braak and Del Tredici, 2011 (Hampel et al., 2010; Wang et al., 2016 (Alzforum, 2016a (Dono hue et al., 2017; Schneider et al., 2014) . Foremost among these approaches may be prevention trials enrolling asymptomatic persons, with character istic neuroimaging pathology or with specific cerebrospinal fluid biomark ers (Donohue et al., 2017; Jansen et al., 2015; Olsson et al., 2016; Ramachan dran, 2016) (Mitchell and Shiri Feshki, 2009; Richard and Brayne, 2014; Roberts et al., 2014a; Ward et al., 2013 (Alperovitch et al., 2014; Sabayan et al., 2013) ; ambulatory (McDonald et al., 2017) ; and home (Matsumoto et al., 2014; Oishi et al., 2017) (Kikuya et al., 2008; Rothwell et al., 2010 ) ; it is un known whether there are shared mechanisms with cognitive decline, and it is also unknown whether specific blood pressure control efforts impact the cog nitive risk (Palatini, 2014) (Ken nelly, Lawlor and Kenny, 2009a; Kennelly, Lawlor and Kenny, 2009b; Purnell et al., 2009; Qiu, Winblad and Fratiglioni, 2005) , with an estimated relative risk of 1.6 (Barnes and Yaffe, 2011 (Hoffman et al., 2016) . This outcome was confirmed in a Swedish study of 186 persons with dementia who participated in an in tensive four-month exercise program (Toots et al., 2017 (Lautenschlager et al., 2008) . In a secondary analysis of the randomized prospective LIFE trial, a 24-month physical activity intervention involving 1,635 sedentary older adults, no exer cise-related improvements were seen in global or domain-specific cognitive function (Sink et al., 2015) .
. Observational studies of h yp ertension and cognitive risk have been heterogeneous, but the evidence is strongest for risk correlation between mid-life h yp ertension and late-life AD and all cause dementia
In (Rolland, Abellan van Kan and Vellas, 2008 (Sofi et al., 2010 (Anastasiou, Ya nnakoulia and Scarmeas, 2014; Guerrero et al., 1999; Joseph et al., 1998; Socci, Crandall and Arendash, 1995; Ya mada et al., 1999 ) . Human stud ies of dietary vitamin intake have shown inconsistent results. Prospective ob servational studies in Chicago (Morris et al., 2002) and Rotterdam (Engelhart et al., 2002) showed lower AD risk with greater dietary vitamin E intake, while a similar study in New Yo rk showed no association (Luchsinger et al., 2003) . The Rotterdam study showed lower AD risk with greater vitamin C intake, but the other two studies did not. The Chicago study also found a worrisome posi tive correlation between vitamin C intake and the risks for h yp ertension and stroke. None of the three studies showed benefit from vitamin C or vitamin E supplements. MCI (46); and demented (182) patients, nor did the levels predict conversion to dementia (Graf et al., 2014) . Conversely, another observational study showed a relative risk for incident AD of 1.69 for deficient and 2.22 for severely deficient vitamin D levels among 1,658 healthy ambulatory adults (Littlejohns et al., 2014) . Over all, human vitamin D study outcomes have been heterogeneous, but the high est quality evidence ( clinical trials) does not support vitamin D-related benefit (Anastasiou, Ya nnakoulia and Scarmeas, 2014) .
In a 2014 study of elderly hospitalized patients, blood levels of 25-hydroxy vitamin D did not discriminate among cognitively normal (200 );
Dietary saturated fat and trans fat intake have been associated with higher AD risks in human studies (Kalmijn et al., 1997; Luchsinger et al., 2002; Mor ris et al., 2003) , though this correlation disappeared during follow-up in one study (Kalmijn et al., 1997 ) . A more recent systematic review revealed mixed evidence among four observational studies of saturated fat and trans fat in take and MCI or dementia (Barnard, Bunner and Agarwal, 2014) . A study of 444 Finnish men linked elevated midlife blood cholesterol with increased subse quent AD risk (Notkola et al., 1998) . Observational studies have reported lower AD risk with statin therapy (lick et al., 2000; Wolozin et al., 2000 ) ; but a 2016 Cochrane review found no benefit on five cognitive tests in two randomized placebo-controlled trials of statins, including 26 1 340 participants (McGuin ness, et al., 2016) . Diets consisting substantially of meat, dairy, processed and fatty foods, snack foods ( often high in trans fats), and high caloric content con tribute to known AD risk factors as well as other health risks.
The pattern of accelerated AD and all-cause dementia after adoption of the American-style diet is widely evident, including in Japan (Grant, 2014) , China (Chan et al., 2013) , rural India (Chandra, et al., 1998) , eight developing nations (Grant, 2014) , and among participants in the Adventist Health Study (Giem, Beeson and Fraser, 1993) . A recent comprehensive review of dietary data and cognitive risks from 2014-2016 presented updated data regarding seafood intake and lines of evidence against cognitive protection, despite the pur ported favorable effects of the omega-3 fatty acids, eicosapentaenoic acid, and docosahexaenoic acid (Solfrizzi et al., 2017 (Asih et al., 2017; Bharadwaj et al., 2017; Sutherland et al., 2017) ; and both disorders have been linked to tau pathology and neurodegeneration (Sutherland et al., 2017 (Barnes and Ya ffe, 2011; Biessels et al., 2006; Biessels et al., 2014; Cheng et al., 2012; Cukierman, Gerstein and Williamson, 2005; Exalto et al., 2012; Gudala et al., 2013; Kopf and Frolich, 2009; Lu, Lin and Kuo, 2009; Roberts, et al., 2014b; Ya ffe, et al., 2012; Zhang et al., 2017 ) , though some of these studies have methodological flaws and unaccounted bias (Sutherland et al., 2017 ) . This correlation was not confirmed for the progression of cognitive decline among AD patients (Li et al., 2017) . Several investigators have estimated the relative risk for AD from T2D M as 1.5 ( Chatterjee et al., 2016; Cheng et al., 2012; Gudala et al., 2013) , including recent population-based stud ies of more than 2.3 million (Chatterjee, et al., 2016) and more than 1.7 million persons (Zhang et al., 2017) . A combined systematic review and meta-analysis of eight studies of T2DM and AD risk reported that seven studies found a posi tive correlation, but only two reached statistical significance, and overall rela tive risk was 1-4- (Lu, Lin and Kuo, 2009 ) .
The risk for development of Mc I, AD, and all-cause dementia increases with T2DM duration (Asih et al., 2017; Bruce et al., 2014) . Dementia risk appears to be proportional to diabetes severity (Yaffe, et al., 2012 ) , to occur at a younger age when T2DM is present (Zilkens et al., 2013) , and to displ ay shorter survival when combined with T2DM (Helzner et al., 2008; Zilkens et al., 2013) human disease, and the Microsoft cofounder stipulated that at least one mem ber of each of the five recipient research teams must not be an AD researcher (Begley, 2016; Paul G. Allen Philanthropies, 2015 (Begley, 2016 
